Search results for "Randomized Controlled Trial"

showing 10 items of 2199 documents

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

2007

Summary Objectives Invasive fungal infections remain a frequent cause of morbidity and mortality in long-term neutropenic patients. The availability of tolerable broad-spectrum antifungals like voriconazole stimulated the discussion about optimal timing of antifungal therapy. We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML). Methods This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy. Oral voriconazole 200mg twice daily or placebo was administered until detection of a lung…

Microbiology (medical)AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentAdministration OralNeutropeniaPlacebolaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansProspective StudiesAgedVoriconazoleLeukopeniaLung Diseases Fungalbusiness.industryIncidenceInduction chemotherapyLength of StayMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesPyrimidinesMycosesFemaleVoriconazolemedicine.symptombusinessmedicine.drugThe Journal of infection
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct

Chronic hepatitis B: who to treat and which choice of treatment?

2009

The goal of antiviral therapy in patients with chronic hepatitis B is to prevent, through persistent suppression of HBV replication, cirrhosis and hepatocellular carcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features of patients, the antiviral efficacy of each drug, the risk of developing resistance, the long-term safety profile, the method of administration and the cost of therapy. Ideal candidates for treatment are hepatitis B e antigen-positive patients with a prolonged phase of immune clearance and hepatitis …

Microbiology (medical)Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularmedicine.disease_causeVirus ReplicationMicrobiologyGastroenterologyAntiviral AgentsDrug Administration ScheduleHepatitis B ChronicPegylated interferonVirologyTelbivudineInternal medicineDrug Resistance ViralmedicineAdefovirHumansRandomized Controlled Trials as TopicHepatitis B virusbusiness.industryNucleotidesLamivudineNucleosidesEntecavirHepatitis Bmedicine.diseaseVirologyInfectious DiseasesPractice Guidelines as TopicHepatitia BbusinessViral hepatitisantiviral Therapymedicine.drugExpert review of anti-infective therapy
researchProduct

Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

2001

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/ day orally in 2 divided doses, or chloramphenicol, 50 mg/ kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P = .047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

Microbiology (medical)Malemedicine.medical_specialtyBoutonneuse FeverGastroenterologylaw.inventionRandomized controlled trialOral administrationlawClarithromycinInternal medicineClarithromycinmedicineHumansChildAntibacterial agentclarithromycin Mediterranean spotted feverbusiness.industryChloramphenicolmedicine.diseaseSpotted feverSurgeryAnti-Bacterial AgentsBoutonneuse feverInfectious DiseasesRickettsiosisChloramphenicolChild PreschoolFemalebusinessmedicine.drug
researchProduct

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

1990

The efficacy and safety of ceftazidime and imipenem in patients with severe infections was compared in a randomized multi-centre trial. Patients on assisted respiration with clinical signs of pneumonia or septicaemia who had been in hospital for at least 3 days were studied. Twenty-one patients were treated with ceftazidime, 24 with imipenem. The mean duration of treatment was 9 days in both groups. At the end of the trial 17 patients (81%) of the ceftazidime group and 16 patients (67%) in the imipenem group were clinically cured or showed marked improvement. The bacteriological results showed an eradication of the causative pathogens in 17 of 21 cases in the ceftazidime group and 13 of 19 …

Microbiology (medical)Malemedicine.medical_specialtyImipenemCeftazidimeHospital-acquired pneumoniaCeftazidimeInternal medicineSepsismedicineHumansMulticenter Studies as TopicIn patientRandomized Controlled Trials as TopicCross Infectionbusiness.industryImipenem/cilastatinGermany WestGeneral MedicinePneumoniaMiddle Agedbacterial infections and mycosesmedicine.diseaseRespiration ArtificialSurgeryClinical trialPneumoniaDrug CombinationsImipenemInfectious DiseasesCilastatinFemalebusinessmedicine.drugThe Journal of hospital infection
researchProduct

Central venous catheter–related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a…

2019

Microbiology (medical)medicine.medical_specialtyEpidemiologybusiness.industrymedicine.medical_treatmentMEDLINElaw.inventionInfectious DiseasesRandomized controlled triallawInternal medicinemedicineIn patientClinical registrybusinessCentral venous catheterInfection Control &amp; Hospital Epidemiology
researchProduct

Consensus document on controversial issues for the treatment of hospital-associated pneumonia

2010

Background: Hospital-associated pneumonia (HAP) remains an important cause of morbidity and mortality despite advances in antimicrobial therapy. Many aspects of the treatment of HAP caused by multi-resistant Gram-positive microorganisms have been extensively studied, but controversial issues remain. Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group – a panel of multidisciplinary experts – was to define recommendations for some controversial issues using an evidence-based and analytical approach. The controversial issues were: (1) Is combination antibiotic therapy or monotherapy more effective in the treatment of HAP? (2) What role do…

Microbiology (medical)medicine.medical_specialtyMEDLINECochrane LibraryGram-Positive BacteriaNosocomial pneumonia Health care-associated pneumonia 16Methicillin-resistant staphylococcilaw.inventionHealth care-associated pneumoniaRandomized controlled triallawSettore MED/41 - ANESTESIOLOGIAPneumonia BacterialHumansMedicineNOSOCOMIAL PNEUMONIAMethicillin-resistant staphylococciIntensive care medicineGram-Positive Bacterial InfectionsRandomized Controlled Trials as TopicCross InfectionEvidence-Based Medicinebusiness.industryBacterial pneumoniaRetrospective cohort studyGeneral MedicineEvidence-based medicinemedicine.diseaseAnti-Bacterial AgentsQuality of evidencePneumoniaTreatment OutcomeInfectious DiseasesDrug Therapy CombinationbusinessInternational Journal of Infectious Diseases
researchProduct

Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives

2021

Background: Urinary tract infections (UTI) are highly frequent in women, with a significant impact on healthcare resources. Although antibiotics still represent the standard treatment to manage recurrent UTI (rUTI), D-mannose, an inert monosaccharide that is metabolized and excreted in urine and acts by inhibiting bacterial adhesion to the urothelium, represents a promising nonantibiotic prevention strategy. The aim of this narrative review is to critically analyze clinical studies reporting data concerning the efficacy and safety of D-mannose in the management of rUTIs. Methods: A non-systematic literature search, using the Pubmed, EMBASE, Scopus, Web of science, Cochrane Central Register …

Microbiology (medical)medicine.medical_specialtymedicine.drug_classUTIAntibiotics030232 urology & nephrologyReviewPlaceboBiochemistryMicrobiologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialpreventionlawInternal medicineMedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsMedical prescriptionProspective cohort studyAdverse effectcystitistreatmentbusiness.industryStandard treatmentlcsh:RM1-950Infectious DiseasesSystematic reviewlcsh:Therapeutics. Pharmacologyfemale030220 oncology & carcinogenesiscystitis; d-mannose; female; prevention; treatment; urinary tract infections; utiurinary tract infectionsbusinessD-mannoseAntibiotics
researchProduct

Changes in emotions and personal goals in primiparous pregnant women during group intervention for fear of childbirth

2018

The changes in emotions, subjective fear of childbirth, and personal goals were examined during a group intervention to treat fear of childbirth (FOC). The objective was to gain a more detailed understanding of the changes occurring during the group intervention of FOC. The changes in emotions, subjective FOC, and personal goals were studied in primiparous pregnant women with severe FOC participating in a group intervention (n = 105). The group intervention contained six sessions during pregnancy and one after childbirth. At every session, the participants filled in a questionnaire regarding their experiences of current positive and negative emotions and the subjective FOC. The participants…

MindfulnessGROUP PSYCHOEDUCATIONgroup interventionlaw.invention0302 clinical medicineRandomized controlled trialPregnancylawSurveys and QuestionnairesAdaptation PsychologicalPARENTHOODMINDFULNESSChildbirthANXIETY030212 general & internal medicinePREDICTORSGeneral Psychologyta515Randomized Controlled Trials as Topic030219 obstetrics & reproductive medicineParentingRelaxation (psychology)Obstetrics and GynecologyFearRANDOMIZED CONTROLLED-TRIALtransition to parenthoodAnxietyFemaleGroup interventionmedicine.symptomPsychologyGoalsClinical psychologyCESAREAN-SECTIONAdult515 PsychologyRELAXATION03 medical and health sciencesIntervention (counseling)medicineHumansMETAANALYSISinterventioPregnancyInfant NewbornParturitionNULLIPAROUS WOMENDelivery Obstetricmedicine.disease3141 Health care sciencechange in emotionsReproductive MedicineFear of childbirthryhmäterapiaPediatrics Perinatology and Child HealthsynnytyspelkoPregnant Womensense organs
researchProduct

The Effects of Acceptance and Commitment Therapy (ACT) Intervention on Inflammation and Stress Biomarkers : a Randomized Controlled Trial

2020

Abstract Background Psychological processes can be manifested in physiological health. We investigated whether acceptance and commitment therapy (ACT), targeted on psychological flexibility (PF), influences inflammation and stress biomarkers among working-age adults with psychological distress and overweight/obesity. Method Participants were randomized into three parallel groups: (1) ACT-based face-to-face (n = 65; six group sessions led by a psychologist), (2) ACT-based mobile (n = 73; one group session and mobile app), and (3) control (n = 66; only the measurements). Systemic inflammation and stress markers were analyzed at baseline, at 10 weeks after the baseline (post-intervention), and…

MindfulnessPsychological interventionbiomarkkeritOverweightAcceptance and commitment therapylaw.inventionjoustavuus0302 clinical medicineMARKERSRandomized controlled triallawWeight lossPsychology030212 general & internal medicinePsychological flexibilityApplied Psychologytietoinen läsnäolotulehdusEATING BEHAVIORylipainoPUBLIC-HEALTH PRACTICEpsykofysiologia3. Good healthHealth psychologyMINDFULNESS-BASED INTERVENTIONCARDIOVASCULAR-DISEASE/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptomMindfulnessAdultmedicine.medical_specialty515 Psychologyhyväksymis- ja omistautumisterapiaPERCEIVED STRESSWEIGHT-LOSSLow-grade inflammationStressFull Length Manuscript03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNORDIC DIETPost-hoc analysismedicineHumansObesityAcceptance and Commitment TherapyInflammationPsykologibusiness.industryCORTISOLstressiOverweightACTPHYSICAL-ACTIVITY3111 BiomedicinebusinessBiomarkers030217 neurology & neurosurgeryfysiologiset vaikutukset
researchProduct